{"altmetric_id":12467160,"counts":{"readers":{"mendeley":27,"citeulike":0,"connotea":0},"total":{"posts_count":4},"news":{"unique_users_count":2,"unique_users":["la_repubblica","corriere_della_sera"],"posts_count":3},"blogs":{"unique_users_count":1,"unique_users":[55854],"posts_count":1}},"citation":{"abstract":"The incidence of prostate cancer is on the rise in many industrialised countries, including Italy, most likely because of the spread of PSA testing. In Italy, prostate cancer mortality has been dropping since 2000, but it is difficult to understand whether PSA testing is the main reason, considering the role of treatment in prognosis. The objectives of this study were: (1) to describe Italian trends of prostate cancer risk categories and corresponding changes in treatment patterns and (2) to interpret changes in survival over time.\nWe made a retrospective observational study using population-based cancer registries. We examined two periods, 1996-1999 and 2005-2007, analysing the distribution of patients among risk groups and treatment changes in those intervals. We estimated 7- and 15-year relative survival with the cohort approach, Ederer II method. We analysed 4635 cases.\nThere was downward risk migration from the first to the second period. In patients younger than 75 years, there was an increase in radical prostatectomy but not radiotherapy; patients older than 75 years rarely had treatment with radical intent. We noted an improvement of prostate cancer survival in the high-risk group.\nThese findings raise several questions: the possible overtreatment of low-risk patients undergoing radical treatment; the utility of more aggressive treatment for elderly patients with high-risk disease; and the importance of a multidisciplinary clinical approach to ensure multiple and alternative treatment options. The increase in survival, with the decrease in mortality, suggests an effect of radical treatments on prognosis.","altmetric_jid":"4f6fa63c3cf058f610008e9a","authors":["Trama, Annalisa","Botta, Laura","Nicolai, Nicola","Rossi, Paolo Giorgi","Contiero, Paolo","Fusco, Mario","Lodde, Michele","Pannozzo, Fabio","Piffer, Silvano","Puppo, Antonella","Seeber, Andreas","Tumino, Rosario","Valdagni, Riccardo","Gatta, Gemma",", "],"doi":"10.1016\/j.ejca.2016.07.021","endpage":"98","first_seen_on":"2016-10-06T11:25:34+00:00","funders":["niehs"],"issns":["1879-0852","09598049"],"journal":"European Journal of Cancer (1965)","last_mentioned_on":1492773512,"links":["https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27620947","http:\/\/www.ejcancer.com\/article\/S0959-8049(16)32346-2\/fulltext","http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959804916323462"],"pmid":"27620947","pubdate":"2016-11-01T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"startpage":"91","subjects":["neoplasms"],"title":"Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study","type":"article","volume":"67","mendeley_url":"http:\/\/www.mendeley.com\/research\/prostate-cancer-changes-clinical-presentation-treatments-two-decades-italian-populationbased-study"},"altmetric_score":{"score":25.04,"score_history":{"1y":25.04,"6m":10,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":25.04},"context_for_score":{"all":{"total_number_of_other_articles":8085159,"mean":6.8783507387159,"rank":334810,"this_scored_higher_than_pct":95,"this_scored_higher_than":7750339,"rank_type":"exact","sample_size":8085159,"percentile":95},"similar_age_3m":{"total_number_of_other_articles":248513,"mean":12.739837625547,"rank":19521,"this_scored_higher_than_pct":92,"this_scored_higher_than":228991,"rank_type":"exact","sample_size":248513,"percentile":92},"this_journal":{"total_number_of_other_articles":1997,"mean":5.0754789579158,"rank":46,"this_scored_higher_than_pct":97,"this_scored_higher_than":1951,"rank_type":"exact","sample_size":1997,"percentile":97},"similar_age_this_journal_3m":{"total_number_of_other_articles":63,"mean":13.346451612903,"rank":6,"this_scored_higher_than_pct":90,"this_scored_higher_than":57,"rank_type":"exact","sample_size":63,"percentile":90}}},"demographics":{"users":{"mendeley":{"by_status":{"Professor > Associate Professor":1,"Librarian":2,"Student  > Doctoral Student":1,"Researcher":3,"Student  > Ph. D. Student":3,"Student  > Postgraduate":2,"Student  > Master":5,"Other":1,"Student  > Bachelor":7,"Lecturer":2},"by_discipline":{"Medicine and Dentistry":12,"Immunology and Microbiology":1,"Agricultural and Biological Sciences":2,"Computer Science":1,"Nursing and Health Professions":4,"Biochemistry, Genetics and Molecular Biology":5,"Pharmacology, Toxicology and Pharmaceutical Science":2}}},"geo":{"mendeley":{"CZ":1}}},"posts":{"news":[{"title":"Tumore alla prostata, dal 2000 mortalit\u00e0 in calo","url":"http:\/\/ct.moreover.com\/?a=28191798411&p=1pl&v=1&x=rKcjG_ha6to2caWhpYzaQA","license":"public","citation_ids":[12467160],"posted_on":"2016-10-06T11:02:16+00:00","summary":"NEGLI ULTIMI anni, dal 2000, \u00e8 calata la mortalit\u00e0 per il tumore alla prostata.","author":{"name":"La Repubblica","url":"http:\/\/www.repubblica.it\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/172\/normal\/image.png?1369926718"}},{"title":"Prostata: sono ancora troppi i tumori non \u00abpericolosi\u00bb che vengono curati","url":"http:\/\/ct.moreover.com\/?a=28271079168&p=1pl&v=1&x=q_W9KOzZtwxiCqycIxfKhA","license":"public","citation_ids":[12467160],"posted_on":"2016-10-13T19:29:13+00:00","summary":"desktop includes2013\/SSI\/notification\/global.json  \/includes2013\/SSI\/utility\/ajax_ssi_loader.shtml Stampa Stampa senza immagine Chiudi STUDIO DELL\u2019ISTITUTO TUMORI DI MILANO Milano, 13 ottobre 2016 - 18:22 Ben\u2026","author":{"name":"Corriere della Sera","url":"http:\/\/www.corriere.it\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/090\/normal\/corriere_della_sera.png?1369846962"}},{"title":"Tumori uro-genitali, Italia al primo posto per guarigioni in Europa","url":"http:\/\/ct.moreover.com\/?a=30310395963&p=1pl&v=1&x=5hlqgB6fv279uRxHXgj6bw","license":"public","citation_ids":[12467160,19505465],"posted_on":"2017-04-21T11:18:32+00:00","summary":"In collaborazione con AIOM Circa 780mila cittadini vivono dopo un carcinoma della prostata, della vescica, del rene e del testicolo.","author":{"name":"La Repubblica","url":"http:\/\/www.repubblica.it\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/172\/normal\/image.png?1369926718"}}],"blogs":[{"title":"Tumore della prostata: la diagnosi precoce salva la vita","url":"https:\/\/www.fondazioneveronesi.it\/articoli\/oncologia\/tumore-della-prostata-la-diagnosi-precoce-salva-la-vita\/","license":"public","citation_ids":[12467160],"posted_on":"2016-10-12T10:53:00+00:00","summary":"Sempre pi&ugrave; diagnosi. Ma anche sempre pi&ugrave; trattamenti. &Egrave; questa l&rsquo;istantanea italiana del tumore della prostata, scattata in due diversi periodi - dal 1996 al 1999 e dal 2005 al 2007 - dai ricercatori dell&rsquo;Istituto Nazionale","author":{"name":"Fondazione Veronesi","url":"https:\/\/www.fondazioneveronesi.it\/rss","description":"Fondazione Veronesi"}}]}}